Current Report Filing (8-k)
March 11 2014 - 5:14PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) |
March 10, 2014 |
NAVIDEA BIOPHARMACEUTICALS, INC. |
(Exact name of registrant as specified in its charter) |
Delaware |
001-35076 |
31-1080091 |
(State or other jurisdiction |
(Commission |
(IRS Employer |
of incorporation) |
File Number) |
Identification No.) |
5600 Blazer Parkway, Suite 200, Dublin, Ohio |
43017 |
(Address of principal executive offices) |
(Zip Code) |
Registrant's telephone number, including area code |
(614) 793-7500 |
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events.
On March 10, 2014, certain senior
executives of Navidea Biopharmaceuticals, Inc. (the “Company”) effected transactions under Rule 144 which
resulted in the acquisition by Platinum Partners Value Arbitrage Fund LP of common stock of the Company held by such senior
executives. The express intent of these transactions is to generate funds required for the senior executives to cover tax
obligations arising from expiring options or the vesting of shares of restricted stock. In connection with such transactions,
four senior executives (Mark Pykett, Chief Executive Officer; Brent Larson, Executive Vice President and Chief Financial
Officer; Fred Cope, Senior Vice President and Chief Scientific Officer; and Rodger Brown, Vice President, Global Quality
Systems and Compliance Policy) sold an aggregate of 200,000 shares of common stock at a per share price of $1.96.
The transactions effected by Drs. Pykett and Cope and Mr. Larson were statutorily required to be matched under Section 16(b)
of the Securities Exchange Act with their respective purchases of: (i) 10,900 shares of common stock at $1.35 per share; (ii)
3,500 shares of common stock at $1.43 per share; and (iii) 5,000 shares of common stock at $1.39 per share, on November 8,
2013. As a result, Drs. Pykett and Cope and Mr. Larson will pay the Company $6,649, $1,855, and $2,850, respectively,
representing the full amount of the profit realized in connection with these short-swing transactions. Each of the officers
has advised the Company that he has no current plans to sell any additional shares of stock.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
Navidea Biopharmaceuticals, Inc. |
|
|
|
|
|
|
Date: March 11, 2014 |
By: |
/s/ Brent L. Larson |
|
|
|
Brent L. Larson, Executive Vice President and
Chief Financial Officer |
|
|
|
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Sep 2023 to Sep 2024